… assessed the value of adding rituximab to conventional chemotherapy for 1,943 patients
with FL, mantle-cell lymphoma, and other indolent lymphomas. This analysis demonstrated …

… the addition of rituximab to chemotherapy for patients with diffuse large B‐cell lymphoma (
DLBCL )… chemotherapy with or without rituximab (R‐ CHOP [rituximab with cyclophosphamide, …

… of CHOP-14 with and without rituximab in 1,222 elderly (61 to 80 … of rituximab to CHOP-like
regimens in a randomized fashion. In total, 3,840 patients with aggressive B-cell lymphoma …

… The impact of rituximab (R) on the incidence of central nervous system (CNS) relapse of
diffuse large B-cell lymphoma (… of CNS relapse of DLBCL in the rituximab era. The risk of CNS …

Diffuse large B‐cell lymphoma (DLBCL) constitutes 25–35% of all non‐Hodgkin lymphomas
in Western countries. Approximately two thirds of the patients can be cured with standard …

… Best response after first-line therapy with rituximab originator (R-originator) or rituximab …
large B-cell lymphoma treated with rituximab originator (R-originator) or rituximab biosimilars (R-…

… Information comparing treatment outcome for diffuse large B cell (DLBCL) and follicular (FL)
non-Hodgkin lymphoma (NHL) patients treated with schemes with and without rituximab …

… However, the rituximab plus CHOP study included patients in first and second relapse and
the rituximab plus FCM study included patients with follicular and mantle cell lymphomas, …

BACKGROUND: Extranodal involvement is considered a poor prognostic factor for patients
with diffuse large B‐cell lymphoma (DLBCL); however, the prognostic impact of specific sites …

… rituximab resistance in diffuse large B-cell lymphoma and its implications in the post-rituximab …
Finally, the role of ASCT in relapsed lymphoma treated with rituximab is questioned, given …